All In Biotech

Drug Trial Radar · NCT06538857

CEB-01 in Locally Resectable Pancreatic Cancer

Exploratory Clinical Trial to Assess Safety, Tolerability Efficacy and Pharmacokinetics of CEB-01 PLGA Membrane in Participants With Pancreatic Cancer.

Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

39

Planned (sponsor's estimate)

Start

Aug 20, 2024

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
CEBIOTEXIndustry
Sponsor type
Industry
Collaborators
MFAR
First posted
Aug 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the pancreatic cancer tumor, CEB 01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of pancreatic cancer after surgery, while keeping a tolerable toxicity profile. The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in patients with locally resectable pancreatic cancer

Conditions

  • Pancreatic Carcinoma

Interventions

  • Standard surgeryProcedure

    The location and size of the tumor determine the type of surgery.

  • CEB-01Drug

    It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs) (Safety)Time frame: Through study completion, average 3 years
  2. Frequency of surgical complications after pancreatic surgeryTime frame: Through study completion, after surgery average 3 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Clínico y Provincial de Barcelona

    Barcelona, Catalonia, Spain

  • H. Clínico San Carlos

    Madrid, Madrid, Spain

  • H.U. Virgen del Rocío

    Seville, Sevilla, Spain

  • H. Clínico Univ. de Valencia

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.